US Physicalrapy Earnings Estimate

USPH Stock  USD 86.94  0.60  0.69%   
By analyzing US Physicalrapy's earnings estimates, investors can diagnose different trends across US Physicalrapy's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for US Physicalrapy is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
US Physicalrapy is projected to generate 0.65885 in earnings per share on the 31st of December 2025. US Physicalrapy earnings estimates show analyst consensus about projected US Physicalrapy EPS (Earning Per Share). It derives the highest and the lowest estimates based on US Physicalrapy's historical volatility. Many public companies, such as US Physicalrapy, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

US Physicalrapy Revenue Breakdown by Earning Segment

By analyzing US Physicalrapy's earnings estimates, investors can diagnose different trends across US Physicalrapy's analyst sentiment over time as well as compare current estimates against different timeframes. As of now, US Physicalrapy's Gross Profit Margin is decreasing as compared to previous years. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.

US Physicalrapy Earnings per Share Projection vs Actual

About US Physicalrapy Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of US Physicalrapy earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current US Physicalrapy estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as US Physicalrapy fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings261.4 M274.4 M
Retained Earnings Total Equity258.1 M158.3 M
Earnings Yield 0.02  0.02 
Price Earnings Ratio 45.45  47.73 
Price Earnings To Growth Ratio 1.33  1.39 

Currently Active Assets on Macroaxis

When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is there potential for Health Care Providers & Services market expansion? Will USPH introduce new products? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.236
Dividend Share
1.79
Earnings Share
2.37
Revenue Per Share
49.547
Quarterly Revenue Growth
0.173
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, US Physicalrapy's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.